Sun Pharmaceutical Industries’ subsidiary has been granted a tentative approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Cardizem CD, Diltiazem HCL extended release capsules. These Diltiazem HCL extended release capsules are equivalent to Valeant international’s, Cardizem CD, 120mg, 180mg, 240mg, 300mg and 360mg. Annual sale in the US for these strengths is about $300 million.
Diltiazem HCL extended release capsules are indicated in the treatment of hypertension, for the management of chronic stable angina and angina due to coronary artery spasm.
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1876.90 |
| Dr. Reddys Lab | 1288.50 |
| Cipla | 1339.55 |
| Zydus Lifesciences | 947.20 |
| Lupin | 2244.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: